Bayer’s Hyrnuo (Sevabertinib) Gains the US FDA Priority Review for 1L Treatment of HER2-Mutated NSCLC

Why It Matters

Priority review shortens the regulatory timeline, enabling faster patient access to a targeted therapy that addresses an unmet need in HER2‑mutated NSCLC and strengthens Bayer’s competitive stance in precision oncology.

Key Takeaways

• FDA grants priority review for Hyrnuo as first‑line NSCLC therapy
• Prior accelerated approval based on ORR and duration of response
• Cohort F data show efficacy in treatment‑naïve HER2‑mutated patients
• Could capture sizable share of $5‑$7 billion NSCLC market
• Strengthens Bayer’s oncology portfolio amid growing targeted‑therapy demand

Pulse Analysis

The presence of activating HER2 (ERBB2) kinase domain mutations defines a distinct molecular subset of non‑small cell lung cancer (NSCLC) that accounts for roughly 2‑3 % of all cases. Patients with these alterations have limited options beyond chemotherapy, and outcomes remain poor. Bayer’s Hyrnuo (sevabertinib) is a selective, irreversible inhibitor designed to block HER2 signaling and downstream proliferation pathways. By targeting the driver mutation directly, Hyrnuo promises a more precise therapeutic approach compared with conventional cytotoxics.

In May 2026 the U.S. Food and Drug Administration granted Hyrnuo priority review for first‑line treatment of adults with locally advanced or metastatic HER2‑mutated NSCLC who have not received systemic therapy. The decision follows encouraging interim results from Cohort F of the Phase I/II SOHO‑01 trial, which demonstrated a high objective response rate and durable disease control in treatment‑naïve patients. Earlier, in November 2025, the drug earned accelerated approval for previously treated patients based on comparable response metrics, setting a clear regulatory pathway toward full approval.

The priority review accelerates Bayer’s entry into a market estimated at $5‑$7 billion globally for HER2‑targeted lung cancer therapies. Competitors such as Roche’s trastuzumab deruxtecan and AstraZeneca’s patritumab‑deruxtecan are already vying for market share, but Hyrnuo’s oral formulation and distinct safety profile could differentiate it. Success would not only bolster Bayer’s oncology pipeline—currently anchored by anti‑angiogenic and immuno‑oncology assets—but also signal growing confidence in mutation‑driven drug development, encouraging further investment in precision‑medicine platforms.